Adverse Drug Reaction Classification System

Pharmaceutical Information
Drug Name Gentamicin
Drug ID BADD_D01016
Description Gentamicin is a bactericidal aminoglycoside that was discovered and isolated from _Micromonospora purpurea_ in 1963.[A234349] It is one of the most frequently prescribed aminoglycosides due to its spectrum of activity, low cost, and availability.[A234339,A234354] Gentamicin is effective against both gram-positive and gram-negative organisms but is particularly useful for the treatment of severe gram-negative infections including those caused by _Pseudomonas aeruginosa_.[A233325,A234359,A234364] There is the added benefit of synergy when gentamicin is co-administered with other antibacterials such as beta-lactams.[A234364] This synergistic activity is not only important for the treatment of complex infections, but can also contribute to dose optimization and reduced adverse effects.[A234359,A234364] Although gentamicin is well-established and may be used in a variety of clinical applications, it is also associated with severe adverse effects including nephrotoxicity and ototoxicity which may limit its use.[A234369]
Indications and Usage For treatment of serious infections caused by susceptible strains of the following microorganisms: P. aeruginosa, Proteus species (indole-positive and indole-negative), E. coli, Klebsiella-Enterobactor-Serratia species, Citrobacter species and Staphylococcus species (coagulase-positive and coagulase-negative).
Marketing Status Prescription; Discontinued
ATC Code D06AX07; J01GB03; S01AA11; S02AA14; S03AA06
DrugBank ID DB00798
KEGG ID D08013
MeSH ID D005839
PubChem ID 3467
TTD Drug ID D0L9UU
NDC Product Code 51662-1508; 63323-173
Synonyms Gentamicins | Gentamycins | Garamycin | Gentacycol | Gentamicin Sulfate | Sulfate, Gentamicin | Gentamicin Sulfate (USP) | Gentavet | Genticin | G-Myticin | G Myticin | GMyticin | Gentamicin | Gentamycin
Chemical Information
Molecular Formula C21H43N5O7
CAS Registry Number 1403-66-3
SMILES CC(C1CCC(C(O1)OC2C(CC(C(C2O)OC3C(C(C(CO3)(C)O)NC)O)N)N)N)NC
Chemical Structure
ADR Related Proteins Induced by Drug
ADR Term Protein Name UniProt AC TTD Target ID PMID
NecrosisSodium/potassium-transporting ATPase subunit alpha-1P05023T408001647125; 1322021; 12905033; 2843053; 1315476; 2563204; 7694338; 11832431
Nephropathy toxicVariant-surface-glycoprotein phospholipase CP09194Not Available6092605; 6307156; 6276533; 3566282; 8663028; 3164751; 2623196; 7876334; 2159723; 8498544; 12039977
Renal impairmentLysosomal Pro-X carboxypeptidaseP42785T20371Not Available
Renal impairmentDipeptidyl aminopeptidase-like protein 6P42658Not AvailableNot Available
Toxicity to various agentsPhospholipase A2P04054T31479Not Available
Toxicity to various agents1-phosphatidylinositol 4,5-bisphosphate phosphodiesterase beta-1Q9NQ66T26846Not Available
ADRs Induced by Drug
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Cardiac arrest02.03.04.0010.000898%
Cerebral infarction24.04.06.002; 17.08.01.0040.001377%Not Available
Chest discomfort08.01.08.019; 02.02.02.009; 22.02.08.0010.002065%Not Available
Chills15.05.03.016; 08.01.09.0010.002754%
Cholestasis09.01.01.0010.004131%Not Available
Cold sweat23.02.03.002; 08.01.03.0240.001377%Not Available
Confusional state19.13.01.001; 17.02.03.005--
Constipation07.02.02.001--
Corneal oedema06.04.02.0010.002065%Not Available
Cough22.02.03.001--
Deafness04.02.01.0010.003442%Not Available
Deafness neurosensory17.04.07.001; 04.02.01.0020.005508%Not Available
Death08.04.01.001--
Dehydration14.05.05.001--
Delirium19.13.02.001--
Depression19.15.01.001--
Dermatitis23.03.04.002--Not Available
Diarrhoea07.02.01.001--
Diffuse large B-cell lymphoma01.15.02.001; 16.28.02.0010.001377%Not Available
Diplopia17.17.01.005; 06.02.06.0020.002065%Not Available
Discomfort08.01.08.0030.001377%Not Available
Disturbance in attention19.21.02.002; 17.03.03.0010.001377%
Dizziness24.06.02.007; 17.02.05.003; 02.01.02.0040.006884%
Drug eruption10.01.01.005; 08.01.06.015; 23.03.05.0010.001377%Not Available
Drug hypersensitivity10.01.01.0010.018588%Not Available
Dysphagia07.01.06.003--
Dyspnoea22.02.01.004; 02.01.03.002--
Encephalopathy17.13.02.001--
Endocarditis11.01.16.001; 02.09.01.0010.000539%
Eosinophilia01.02.04.0010.002065%
The 2th Page    First    Pre   2 3 4 5 6    Next   Last    Total 8 Pages